Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases
Recruiting
N/A
Interventional Study
Metabolic Dysfunction-associated Steatotic Liver Disease
Hepatic Steatosis
Non-alcoholic Fatty Liver Diseases
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 150 (estimated)
- Sponsor
- Jinling Hospital, China · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn if hyperbaric oxygen therapy (HBOT) works to treat Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD). The main questions it aims to answer are:
Does HBOT decreases the fat content and fibrosis state of liver in adult MASLD patients? Does HBOT improves the liver function and metabolic condition in adult MASLD patients?
Participants will:…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Metabolic dysfunction-associated steatotic liver disease patients
Exclusion Criteria:
* Participants are unfit for hyperbaric treatment.
* Participants with prior oxygen therapy within the last 6 months.
* Participants with history of viral hepatitis, hemochromatosis, Wilson…
Contacts